Stocks to Watch: RITES, Mishtann Foods, Canara Bank, and Dr. Reddy Labs

Stocks in Focus: What’s Really Going On With Mishtann, RITES, Canara Bank, and Dr. Reddy’s?

It’s been an eventful few weeks in the markets—and if you’re following regulatory action or business moves closely, four names have stood out for very different reasons: Mishtann Foods, RITES Ltd, Canara Bank, and Dr. Reddy’s Laboratories. From SEBI crackdowns to RBI green lights and expansionary deals, here’s a closer look at what’s unfolding beneath the headlines—and what it might mean for investors watching from the sidelines.

Mishtann Foods: Under the SEBI Scanner, and the Market's Wrath

If there’s one stock that’s felt the full force of regulatory heat, it’s Mishtann Foods. SEBI came down hard with an order that could fundamentally reshape the company’s future. At the heart of the matter is a ₹100-crore recovery directive—money the regulator believes was siphoned off through dubious transactions and circular trading with shell entities tied to insiders.

This isn’t just a slap on the wrist. Mishtann, along with its Chairman and Managing Director Hiteshkumar Gaurishankar Patel and other top executives, has been barred from accessing the capital markets or raising funds from the public—indefinitely. Several executives have also been blocked from engaging with any SEBI-registered or listed entity.

The market’s reaction? Swift and brutal. The stock was locked in lower circuits, tanking by 20%, as investors tried to process the fallout.

SEBI also flagged another troubling sign: the company’s shareholder base exploded from just over 500 in FY18 to more than 4.2 lakh by September 2024. That kind of jump raises serious governance concerns, and the regulator isn’t taking it lightly.

Mishtann, for its part, has denied wrongdoing and says it plans to fight back legally. But until the dust settles, the stock may remain radioactive for many cautious investors.

RITES Ltd: Quiet Win, Big Implications

While Mishtann grabbed headlines for all the wrong reasons, RITES Ltd quietly notched a significant win. The government-owned engineering consultancy has been appointed as the Project Management Consultant for Phase II of IIM Raipur’s new campus—a ₹148.25 crore contract with a 23-month timeline.

What stands out here isn’t just the size of the deal, but the prestige attached to it. Winning a high-profile institutional project like this solidifies RITES' reputation in the infrastructure and consultancy space. Importantly, the company clarified that this isn’t a related-party transaction, underscoring its commitment to SEBI compliance norms.

For investors, this contract might signal reliable revenue streams over the next two years—and continued dominance in its niche sector.

Canara Bank: Strategic Divestment, RBI-Approved

On the banking front, Canara Bank just crossed a major regulatory hurdle. The Reserve Bank of India has officially cleared its plan to offload a 13% stake in Canara Robeco Asset Management and a 14.5% stake in Canara HSBC Life Insurance—both through upcoming IPOs.

This is more than just another asset sale. The RBI has mandated that Canara Bank bring its ownership in both these subsidiaries down to 30% by October 2029. This push aligns with broader efforts to separate core banking from auxiliary businesses and unlock value where it makes sense.

Strategically, the move allows the bank to sharpen its focus, free up capital, and stay on the right side of both regulatory and internal portfolio optimization goals. For shareholders, there’s a potential bonus: value unlocking through these IPOs could offer a fresh upside.

Dr. Reddy’s: Strong Numbers, Stronger Intent

In pharma, Dr. Reddy’s Laboratories has been quietly building momentum. The company announced a final dividend of ₹8 per share for FY25 (record date: July 10), off the back of solid numbers. Full-year revenue came in at ₹3,25,535 million, while EBITDA stood at ₹92,133 million. The company’s fourth-quarter net profit jumped 22% to ₹1,594 crore, thanks largely to robust performance across international markets.

The first quarter of FY25 has also started on a strong note, with revenue up 14% year-on-year—mainly driven by volume growth in the U.S. and an expanding product pipeline.

But Dr. Reddy’s isn’t just riding the wave; it's making waves. The company recently acquired a nicotine replacement product line (Nicotinell) and struck a strategic nutrition joint venture with Nestlé India. Add to that multiple biosimilar partnerships—with names like Alvotech, Henlius, and Bio-Thera Solutions—and it’s clear Dr. Reddy’s is positioning itself for the next frontier of pharma growth.

Management remains optimistic about sustaining double-digit growth into FY26. There’s clear emphasis on complex generics and biologics, though caution remains as key drug patents (like Revlimid) edge closer to expiry. That said, their innovation pipeline might just be strong enough to offset potential cliffs.

Quick Summary: What to Watch

Company	Regulatory/Business Update	What It Means
Mishtann Foods	SEBI orders ₹100 cr recovery, bans, scrutiny on governance	High compliance and trading risk
RITES	₹148.25 cr IIM Raipur PMC contract	Revenue uptick and enhanced credibility
Canara Bank	RBI clears divestments; 30% stake mandate by 2029	Regulatory alignment, sharper focus, capital optimisation
Dr. Reddy’s Labs	₹8 dividend, strong FY25/Q1, biosimilar and NRT deals	Solid financial base, future-ready innovation strategy

Final Word

From SEBI enforcement action to strategic business pivots and expansion bets, these four companies are undergoing meaningful transformations—each in its own way. For investors, that means risk in some places and opportunity in others. Staying informed and understanding the nuance behind each headline is what will separate reactionary trading from thoughtful investing.